Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Blood (2023) 142 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2023-178645

Published: 2023

Journal Articles

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Miriam A. Osei, Lauren E. Merz, Kelly S. Chien, Danielle E. Hammond, Coleman Lindsley, Marlise R. Luskin, Maximilian Stahl, Joan How, Mohammed Wazir, Anna E. Marneth, Shai Shimony, Ann Mullally, Daniel J. DeAngelo, Guillermo Garcia-Manero, Maureen Okam Achebe, Benjamin L. Ebert, Lachelle D. Weeks

Blood (2023) 142 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2023-172992

Published: 2023

Journal Articles

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Joan How, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Donna S. Neuberg, Siyang Ren, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Sahand Hormoz, Ann Mullally

Blood (2023) 142 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2023-179407

Published: 2023

Journal Articles

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Mahasweta Gooptu, Haesook T. Kim, Kaina Chen, Ann Mullally, Joseph Antin, Corey Cutler, Amar H Kelkar, John Koreth, Roman M. Shapiro, Robert J. Soiffer, Daniel J. DeAngelo, Jacqueline S. Garcia, Marlise R. Luskin, Richard M Stone, Martha Wadleigh, Eric S. Winer, R. Coleman Lindsley, Vincent Ho

Blood (2023) 142 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2023-178684

Published: 2023

Journal Articles

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Benjamin Rolles, Cilomar Martins De Oliveira Filho, Julia Keating, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Jessica Hem, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Harrison K. Tsai, Maximilian Stahl, Ann Mullally

Blood (2023) 142 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2023-185024

Published: 2023

Journal Articles

Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms

Swarna Bale, Chulwoo J. Kim, Joan How, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Ann Mullally, Anna E. Marneth

Blood (2023) 142 (Supplement 1): 1788.

https://doi.org/10.1182/blood-2023-178657

Published: 2023

Journal Articles

Biology and therapeutic targeting of molecular mechanisms in MPNs

Joan How, Jacqueline S. Garcia, Ann Mullally

Blood (2023) 141 (16): 1922–1933.

https://doi.org/10.1182/blood.2022017416

Published: 2023

Journal Articles

Two to tango! IL-13 and TGF-β drive myelofibrosis

Jonas S. Jutzi, Ann Mullally

Blood (2022) 140 (26): 2767–2768.

https://doi.org/10.1182/blood.2022018859

Published: 2022

Includes: Supplemental data

Journal Articles

Mutant Asxl1 Exacerbates the MPN Phenotype of Calr del52 Mutant Mice with Distinct Effects on Histone H3 Modifications in Megakaryocytes

Frederike Kramer, Anna E Marneth, Olga Pozdnyakova, Jessica Hem, Malvina Papanastasiou, Andrew Reiter, Steven A Carr, Ann Mullally

Blood (2022) 140 (Supplement 1): 9575–9576.

https://doi.org/10.1182/blood-2022-167735

Published: 2022

Journal Articles

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Anna E Marneth, Jonas S. Jutzi, Chulwoo J. Kim, Charles Laurore, Anastasia Tishena, Frederike Kramer, Azucena V. Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian F. Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Timothy A. Graubert, Ann Mullally

Blood (2022) 140 (Supplement 1): 1089–1090.

https://doi.org/10.1182/blood-2022-158823

Published: 2022

Journal Articles

Whole-genome CRISPR screening identifies N- glycosylation as a genetic and therapeutic vulnerability in CALR -mutant MPNs

Jonas S. Jutzi, Anna E. Marneth, Michele Ciboddo, Angel Guerra-Moreno, María José Jiménez-Santos, Anastasia Kosmidou, James W. Dressman, Hongyan Liang, Rebecca Hamel, Patricia Lozano, Elisa Rumi, John G. Doench, Jason Gotlib, Anandi Krishnan, Shannon Elf, Fátima Al-Shahrour, Ann Mullally

Blood (2022) 140 (11): 1291–1304.

https://doi.org/10.1182/blood.2022015629

Published: 2022

Includes: Supplemental data

Journal Articles

Whole-Genome CRISPR Screening Identifies N -Glycosylation As an Essential Pathway and a Potential Novel Therapeutic Target in CALR -Mutant MPN

Anna E. Marneth, Jonas S. Jutzi, Angel Guerra-Moreno, Michele Ciboddo, María José Jiménez Santos, Anastasia Kosmidou, Rebecca Hamel, Patricia Lozano, Elisa Rumi, John G. Doench, Jason Gotlib, Anandi Krishnan, Shannon Elf, Fatima Al-Shahrour, Ann Mullally

Blood (2021) 138 (Supplement 1): 58.

https://doi.org/10.1182/blood-2021-149218

Published: 2021

Journal Articles

Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Matrix

Kyle H Vining, Anna E. Marneth, Kwasi Adu-Berchie, Christina M. Tringides, Joshua M Grolman, Yutong Liu, Waihay J. Wong, Olga Pozdnyakova, Mariano Severgnini, Alexander Stafford, Georg N. Duda, Ann Mullally, Kai W. Wucherpfennig, David J Mooney

Blood (2021) 138 (Supplement 1): 2539.

https://doi.org/10.1182/blood-2021-147297

Published: 2021

Journal Articles

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141643

Published: 2020

Journal Articles

Both sides now: losses and gains of mutant CALR

Ann Mullally

Blood (2020) 135 (2): 82–83.

https://doi.org/10.1182/blood.2019003820

Published: 2020

Journal Articles

Mutant calreticulin in myeloproliferative neoplasms

Joan How, Gabriela S. Hobbs, Ann Mullally

Blood (2019) 134 (25): 2242–2248.

https://doi.org/10.1182/blood.2019000622

Published: 2019

Journal Articles

Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model

Thiago Mantello Bianco, MSc, Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Priscila Santos Scheucher, PhD, Isabel Weinhäuser, MSc, Antonio Bruno Alves Silva, BSc, Cleide Lucia Silva, MSc, Ann Mullally, MD, Susumu S Kobayashi, MD PhD, Eduardo M Rego, MD PhD, Fabiola Traina, MD PhD, Lorena Lobo Figueiredo-Pontes, MD PhD

Blood (2019) 134 (Supplement_1): 2977.

https://doi.org/10.1182/blood-2019-131023

Published: 2019

Journal Articles

Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN Pathogenesis

Jeanne F Rivera, BSc, April Joy Baral, MSc, Rachael Smyth, MSc, Fatima Nadat, PhD, Emma Burman, BSc, Ghadah Alameer, MSc, Sally A Boxall, PhD, Brian R Jackson, PhD, Ann Mullally, MD, Edwin Chen, PhD

Blood (2019) 134 (Supplement_1): 312.

https://doi.org/10.1182/blood-2019-124005

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera

Chi-Joan How, MD, Orly Leiva, BS, Thomas Bogue, BS, Geoffrey Fell, MS, Mark Bustoros, MD, Nathan T. Connell, MD MPH, Jean M. Connors, MD, Irene M. Ghobrial, MD, Nancy Higgins, Nicholas A Jessop, David J. Kuter, Jennifer Lombardi Story, Ann Mullally, MD, Valentina Nardi, MD, Donna S Neuberg, ScD, Rachel Styles, BS, Jeffrey I. Zwicker, MD, Gabriela S. Hobbs, MD, Annemarie E Fogerty, MD

Blood (2019) 134 (Supplement_1): 4172.

https://doi.org/10.1182/blood-2019-127058

Published: 2019

NARROW

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms

Biology and therapeutic targeting of molecular mechanisms in MPNs

Two to tango! IL-13 and TGF-β drive myelofibrosis

Mutant Asxl1 Exacerbates the MPN Phenotype of Calr del52 Mutant Mice with Distinct Effects on Histone H3 Modifications in Megakaryocytes

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Whole-genome CRISPR screening identifies N- glycosylation as a genetic and therapeutic vulnerability in CALR -mutant MPNs

Whole-Genome CRISPR Screening Identifies N -Glycosylation As an Essential Pathway and a Potential Novel Therapeutic Target in CALR -Mutant MPN

Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Matrix

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

Both sides now: losses and gains of mutant CALR

Mutant calreticulin in myeloproliferative neoplasms

Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model

Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN Pathogenesis

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only